The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
BIOBOARD - INSIDE INDUSTRY
Biametrics successfully finalizes feasibility study with MorphoSys in the area of high-throughput antibody screening
Biametrics GmbH and MorphoSys AG plan to further collaborate in the area of high-throughput antibody screening.

Biametrics performed a very successful screening study using MorphoSys' reagents and Biametrics' label-free microarray based instrumentation b-screen for the characterization of Fab fragment antigen interactions. The feasibility study clearly demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format. Recently, Biametrics launched their b-screen device for high-throughput biomolecular interaction screening/analysis.

"We are delighted to be collaborating with MorphoSys, a leader in the development of biotherapeutics," said Dr. Florian Pröll, Managing Director of Biametrics "We look forward to expand our collaboration in the field of biomolecular interaction analysis."

Biametrics' b-screen device enables the detection of these biomolecules in a high-density array format on microscope slide disposables. Thereby, no fluorescence labels are needed for read-out. This leads to minimized sample pre-treatment and reagent consumption. With this new optical detection method, it is possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.

"We have identified b-screen as an promising technology in the field of epitope mapping, and will now broaden our collaboration with Biametrics", added Dr. Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys AG.

The collaboration between MorphoSys AG as a globally established supplier of therapeutic antibodies and Biametrics as an aspiring technology company allows for a fast and successful development of such biopharmaceuticals. MorphoSys will continue the cooperation with Biametrics.

Source: B3C Newswire

Click here for the complete issue.